Table 2.

Th17 cells, serum IL-17, and IL-23 levels with respect to disease activity parameters and immunosuppressants.

Activity measured by NIH criteria
	Active (n = 13)	Inactive (n = 17)	p value (Mann-Whitney)
Th17 cells (%)	2.1 (1.4–3)	2.05 (1.6–4.3) (n = 16∗)	0.55
IL-17A (pg/mL)	7.4 (4.7–9)	5.3 (4.4–8.5)	0.56
IL-23 (pg/mL)	14.9 (14.9–17.7)	15 (14.9–30.5)	0.07
Activity measured by ITAS2010 ≥ 4
	Active (n = 12)	Inactive (n = 18)	p value (Mann-Whitney)
Th17 cells (%)	2.2 (1.4–3.1)	1.9 (1.6–4.2) (n = 17∗)	0.80
IL-17A (pg/mL)	7.7 (4.7–9.2)	5.4 (4.4–8.6)	0.54
IL-23 (pg/mL)	14.9 (14.9–19)	15 (14.9–28.7)	0.13
Data with respect to immunosuppressants
	Not on immunosuppressants (n = 13)	On immunosuppressants∗∗ (n = 17)	p value (Mann-Whitney)
Th17 cells (%)	2 (1.3–2.8)	2.3 (1.6–3.8) (n = 16∗)	0.30
IL-17A (pg/mL)	6.5 (4.7–9)	6.1 (4.4–8.6)	0.85
IL-23 (pg/mL)	14.9 (14.9–20.6)	15 (14.9–26.6)	0.36

Values represented as median with interquartile range in brackets.

^∗Th17 cell population could not be studied in one patient due to technical difficulties.

^∗∗14 patients were on prednisolone, 11 on oral methotrexate, and 3 on azathioprine.